WuXi Biologics Boosts Complex Biologics Pipeline
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
WuXi Biologics has expanded its role as a global CRDMO partner in next-generation biologics with two new strategic agreements focused on complex modalities for autoimmune and oncology indications.
In one collaboration, the company will support Sinorda Biomedicine in advancing SND006, an innovative bispecific antibody for inflammatory bowel disease and other autoimmune diseases, by providing integrated development and manufacturing services from preclinical pharmacology through clinical supply to accelerate planned IND filings in China and the United States.
Pingsheng Hu, Chairman and General Manager of Sinorda Biomedicine, commented, “We believe this collaboration will accelerate the IND filings of our innovative biologics in China and worldwide, address unmet medical needs in autoimmune diseases, and ultimately bring safe and effective therapies to patients.”
In parallel, a partnership with HanchorBio will see WuXi Biologics deliver end-to-end CMC and GMP capabilities for multiple bi- and multi-functional fusion protein programs emerging from HanchorBio’s Fc-Based Designer Biologics platform, with the aim of improving execution speed, scalability, and global readiness for a multi-asset immunotherapy pipeline targeting cancer and immune disorders.
Chris Chen, Chief Executive Officer of WuXi Biologics, said: ” We are excited to embark on this collaboration with HanchorBio, which underscores the strong trust they placed in WuXi Biologics’ comprehensive, end-to-end capabilities for developing next-generation biologics, especially complex molecules. By leveraging our industry-leading technology platforms, proven expertise, and unwavering commitment to quality, we strive to accelerate the development of HanchorBio’s innovative bi-/multi-fusion proteins and help bring transformative therapies to patients worldwide."
Company
